JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis

Detalhes bibliográficos
Autor(a) principal: Moura, Rita
Data de Publicação: 2021
Outros Autores: Fonseca, João Eurico
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/46766
Resumo: Copyright © 2021 Moura and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC BY). The use,distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use,distribution or reproduction is permitted which does not comply with these terms
id RCAP_ca279d04bd4658660ba6cb88cd9c7708
oai_identifier_str oai:repositorio.ul.pt:10451/46766
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritisB cellsJAK inhibitorsJAK-STAT pathwayCytokinesRheumatoid arthritisCopyright © 2021 Moura and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC BY). The use,distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use,distribution or reproduction is permitted which does not comply with these termsRheumatoid arthritis (RA) is a chronic, systemic immune-mediated inflammatory disease that can lead to joint destruction, functional disability and substantial comorbidity due to the involvement of multiple organs and systems. B cells have several important roles in RA pathogenesis, namely through autoantibody production, antigen presentation, T cell activation, cytokine release and ectopic lymphoid neogenesis. The success of B cell depletion therapy with rituximab, a monoclonal antibody directed against CD20 expressed by B cells, has further supported B cell intervention in RA development. Despite the efficacy of synthetic and biologic disease modifying anti-rheumatic drugs (DMARDs) in the treatment of RA, few patients reach sustained remission and refractory disease is a concern that needs critical evaluation and close monitoring. Janus kinase (JAK) inhibitors or JAKi are a new class of oral medications recently approved for the treatment of RA. JAK inhibitors suppress the activity of one or more of the JAK family of tyrosine kinases, thus interfering with the JAK-Signal Transducer and Activator of Transcription (STAT) signaling pathway. To date, there are five JAK inhibitors (tofacitinib, baricitinib, upadacitinib, peficitinib and filgotinib) approved in the USA, Europe and/ or Japan for RA treatment. Evidence from the literature indicates that JAK inhibitors interfere with B cell functions. In this review, the main results obtained in clinical trials, pharmacokinetic, in vitro and in vivo studies concerning the effects of JAK inhibitors on B cell immune responses in RA are summarized.FrontiersRepositório da Universidade de LisboaMoura, RitaFonseca, João Eurico2021-03-10T12:17:24Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/46766engFront Med (Lausanne). 2021 Feb 5;7:607725.10.3389/fmed.2020.6077252296-858Xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:49:13Zoai:repositorio.ul.pt:10451/46766Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:58:50.724668Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
title JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
spellingShingle JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
Moura, Rita
B cells
JAK inhibitors
JAK-STAT pathway
Cytokines
Rheumatoid arthritis
title_short JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
title_full JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
title_fullStr JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
title_full_unstemmed JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
title_sort JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
author Moura, Rita
author_facet Moura, Rita
Fonseca, João Eurico
author_role author
author2 Fonseca, João Eurico
author2_role author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Moura, Rita
Fonseca, João Eurico
dc.subject.por.fl_str_mv B cells
JAK inhibitors
JAK-STAT pathway
Cytokines
Rheumatoid arthritis
topic B cells
JAK inhibitors
JAK-STAT pathway
Cytokines
Rheumatoid arthritis
description Copyright © 2021 Moura and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC BY). The use,distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use,distribution or reproduction is permitted which does not comply with these terms
publishDate 2021
dc.date.none.fl_str_mv 2021-03-10T12:17:24Z
2021
2021-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/46766
url http://hdl.handle.net/10451/46766
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Front Med (Lausanne). 2021 Feb 5;7:607725.
10.3389/fmed.2020.607725
2296-858X
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers
publisher.none.fl_str_mv Frontiers
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134534245023744

Registros relacionados